vs
Side-by-side financial comparison of LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) and NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP (NEN). Click either name above to swap in a different company.
LIFECORE BIOMEDICAL, INC. \DE\ is the larger business by last-quarter revenue ($31.1M vs $23.6M, roughly 1.3× NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP). LIFECORE BIOMEDICAL, INC. \DE\ runs the higher net margin — -32.1% vs -677.3%, a 645.2% gap on every dollar of revenue. On growth, NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP posted the faster year-over-year revenue change (15.7% vs -4.5%). Over the past eight quarters, NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP's revenue compounded faster (8.9% CAGR vs -0.1%).
LIFECORE BIOMEDICAL, INC. is a biomedical firm focused on developing and manufacturing high-quality hyaluronic acid-based biomaterials. It operates three core segments: medical application products, pharmaceutical solutions, and personal care ingredients, with main markets spanning North America, Europe and the Asia-Pacific, supplying to leading medical device, pharmaceutical and cosmetic brand partners.
New England Realty Associates Limited Partnership is a real estate investment entity that owns, operates and manages residential and commercial properties primarily across the U.S. New England region. Its core assets include multifamily apartments, mixed-use properties and small commercial spaces, serving tenants across Massachusetts, New Hampshire and adjacent states, delivering steady returns to unitholders via rental income and property value growth.
LFCR vs NEN — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $31.1M | $23.6M |
| Net Profit | $-10.0M | $-1.4M |
| Gross Margin | 25.0% | — |
| Operating Margin | -9.9% | 14.0% |
| Net Margin | -32.1% | -677.3% |
| Revenue YoY | -4.5% | 15.7% |
| Net Profit YoY | -52.0% | -133.0% |
| EPS (diluted) | $-0.29 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $23.6M | ||
| Q3 25 | $31.1M | $23.7M | ||
| Q2 25 | — | $21.2M | ||
| Q1 25 | $35.2M | $20.7M | ||
| Q4 24 | $32.6M | $20.4M | ||
| Q3 24 | $24.7M | $20.2M | ||
| Q2 24 | — | $20.1M | ||
| Q1 24 | $35.7M | $19.9M |
| Q4 25 | — | $-1.4M | ||
| Q3 25 | $-10.0M | $-521.8K | ||
| Q2 25 | — | $4.1M | ||
| Q1 25 | $-14.8M | $3.8M | ||
| Q4 24 | $-6.6M | $4.2M | ||
| Q3 24 | $-16.2M | $3.9M | ||
| Q2 24 | — | $4.1M | ||
| Q1 24 | $15.6M | $3.5M |
| Q4 25 | — | — | ||
| Q3 25 | 25.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 28.0% | — | ||
| Q4 24 | 34.0% | — | ||
| Q3 24 | 21.8% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 33.3% | — |
| Q4 25 | — | 14.0% | ||
| Q3 25 | -9.9% | 20.0% | ||
| Q2 25 | — | 33.3% | ||
| Q1 25 | -25.7% | 30.1% | ||
| Q4 24 | -6.0% | 32.4% | ||
| Q3 24 | -46.9% | 32.0% | ||
| Q2 24 | — | 32.6% | ||
| Q1 24 | -2.5% | 28.9% |
| Q4 25 | — | -677.3% | ||
| Q3 25 | -32.1% | -2.2% | ||
| Q2 25 | — | 19.5% | ||
| Q1 25 | -42.0% | 18.3% | ||
| Q4 24 | -20.2% | 20.7% | ||
| Q3 24 | -65.7% | 19.3% | ||
| Q2 24 | — | 20.3% | ||
| Q1 24 | 43.8% | 17.4% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.29 | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-0.47 | — | ||
| Q4 24 | $-0.25 | — | ||
| Q3 24 | $-0.53 | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $0.42 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.9M | $26.7M |
| Total DebtLower is stronger | $136.0M | $531.0M |
| Stockholders' EquityBook value | $-10.5M | — |
| Total Assets | $235.2M | $505.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $26.7M | ||
| Q3 25 | $18.9M | $13.4M | ||
| Q2 25 | — | $16.7M | ||
| Q1 25 | $5.4M | $30.9M | ||
| Q4 24 | $9.5M | $17.6M | ||
| Q3 24 | — | $15.1M | ||
| Q2 24 | — | $13.5M | ||
| Q1 24 | — | $28.8M |
| Q4 25 | — | $531.0M | ||
| Q3 25 | $136.0M | $514.2M | ||
| Q2 25 | — | $514.3M | ||
| Q1 25 | $124.9M | $407.8M | ||
| Q4 24 | $111.3M | $408.6M | ||
| Q3 24 | $106.3M | $409.3M | ||
| Q2 24 | — | $410.0M | ||
| Q1 24 | $97.1M | $410.7M |
| Q4 25 | — | — | ||
| Q3 25 | $-10.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $2.2M | — | ||
| Q4 24 | $15.4M | — | ||
| Q3 24 | $-3.9M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $17.7M | — |
| Q4 25 | — | $505.3M | ||
| Q3 25 | $235.2M | $492.9M | ||
| Q2 25 | — | $494.8M | ||
| Q1 25 | $237.7M | $385.2M | ||
| Q4 24 | $255.4M | $393.5M | ||
| Q3 24 | $246.8M | $387.4M | ||
| Q2 24 | — | $383.7M | ||
| Q1 24 | $246.2M | $381.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 56.05× | — | ||
| Q4 24 | 7.20× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 5.49× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8M | $27.7M |
| Free Cash FlowOCF − Capex | $25.0K | — |
| FCF MarginFCF / Revenue | 0.1% | — |
| Capex IntensityCapex / Revenue | 5.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-16.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $27.7M | ||
| Q3 25 | $1.8M | $2.3M | ||
| Q2 25 | — | $12.5M | ||
| Q1 25 | $1.2M | $5.5M | ||
| Q4 24 | $-6.1M | $31.9M | ||
| Q3 24 | $-613.0K | $8.5M | ||
| Q2 24 | — | $5.4M | ||
| Q1 24 | $-1.4M | $6.1M |
| Q4 25 | — | — | ||
| Q3 25 | $25.0K | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-4.3M | — | ||
| Q4 24 | $-8.6M | — | ||
| Q3 24 | $-4.0M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-7.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -12.1% | — | ||
| Q4 24 | -26.3% | — | ||
| Q3 24 | -16.3% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -21.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 5.6% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 15.5% | — | ||
| Q4 24 | 7.5% | — | ||
| Q3 24 | 13.9% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 17.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 3.02× | ||
| Q1 25 | — | 1.44× | ||
| Q4 24 | — | 7.57× | ||
| Q3 24 | — | 2.17× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | -0.09× | 1.77× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LFCR
| Transferred At Point In Time | $26.6M | 85% |
| Transferred Over Time | $4.5M | 15% |
NEN
Segment breakdown not available.
